Abstract
Invasive ductal carcinoma (IDC) is one of the most common types of invasive breast cancer. Many mutations have been associated with IDC which continue to guide disease prevention protocols. Studies have shown that variations in this the LZTR1 gene enhance RAS-MAPK signaling which is involved in cell growth, division, and differentiation1. Mapping such genetic mutations has been an essential tool used to prevent disease, treat cancers, and to establish a prognosis. This case study focuses on LZTR1 gene mutation and its implication in IDC and other cancers.
